A New Standard of Care in HER2 Breast Cancer

MADRID (MedPage Today) -- Adding two anti-HER2 agents to chemotherapy for metastatic disease increases media survival to almost 5 years.
Source: MedPage Today Geriatrics - Category: Geriatrics Source Type: news